Akkermansia muciniphila

Evidence Fact Sheet

next-generation probiotic

Akkermansia muciniphila is a mucin-degrading gut commensal studied as a next-generation probiotic, usually as pasteurized cells. Early human RCTs explore metabolic and weight-maintenance markers; it is an authorized EU novel food and a lawful US dietary ingredient, with no authorized health claim.

Also known as: A. muciniphila · Akkermansia · Pasteurized Akkermansia muciniphila · AKK · Next-generation probiotic

Overview

Akkermansia muciniphila is a mucin-degrading gut commensal developed as a "next-generation" probiotic, most often supplied in a pasteurized form whose Amuc_1100 outer-membrane protein retains activity. Proposed mechanisms (largely preclinical and early human) include strengthening the intestinal mucus layer and gut barrier via TLR2 signaling, and modulation of insulin sensitivity, lipid markers, and GLP-1/gut-hormone pathways. The pivotal exploratory human study used roughly 10^10 cells/day of pasteurized cells for three months; EU novel-food authorization caps adult use at <=3.4x10^10 cells/day (excluding pregnant/lactating women and children). Regulatory status: pasteurized A. muciniphila is an authorized EU novel food (Reg (EU) 2022/168) and a lawful US dietary ingredient via FDA NDI notification and self-affirmed GRAS, with structure/function claims only and no FDA- or EFSA-authorized health claim; it is pending/unlisted in China and Brazil. Human efficacy evidence is early (evidence grade C).

Mechanism of Action

Mucin-degrading gut commensal that stimulates host mucus turnover and strengthens the intestinal mucus layer / gut barrier (research context) · Amuc_1100 outer-membrane protein activates TLR2 signaling to improve gut-barrier integrity (preclinical · pasteurized form retains activity) · Improvement of metabolic markers (insulin sensitivity, lipid profile) in early human and animal studies (research context) · Modulation of GLP-1 and gut-hormone / energy-metabolism pathways (preclinical / early human) · Anti-inflammatory modulation of the gut-immune axis (preclinical)

Body systems: Digestive & Gut · Immune System

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Akkermansia muciniphila is not characterized as a treatment for any disease.

Insulin Sensitivity & Metabolic Markers

RCT supported

+28.62 ± 7.02%insulin sensitivity · P=0.002
-34.08 ± 7.12%insulinemia · P=0.006
32 completedn · 3-month pilot

In this pivotal proof-of-concept randomized, double-blind, placebo-controlled pilot in overweight/obese volunteers, three months of pasteurized A. muciniphila (~10^10 cells/day) improved insulin sensitivity and lowered insulinemia and total cholesterol versus placebo. This is the single anchor human trial behind the metabolic research context; it was exploratory (40 enrolled, 32 completed) and framed as hypothesis-generating, not confirmatory.

Reported effect: Pasteurized A. muciniphila improved insulin sensitivity (+28.62 ± 7.02%, P = 0.002), reduced insulinemia (-34.08 ± 7.12%, P = 0.006) and reduced plasma total cholesterol (-8.68 ± 2.38%, P = 0.02)

“Pasteurized A. muciniphila improved insulin sensitivity (+28.62 ± 7.02%, P = 0.002), reduced insulinemia (-34.08 ± 7.12%, P = 0.006) and reduced plasma total cholesterol (-8.68 ± 2.38%, P = 0.02) ... 40 were enrolled and 32 completed the trial ... the intervention was safe and well tolerated”

Source: PMID 31263284 · Depommier 2019 · Nat Med

Type 2 Diabetes / Weight — Overall Null

Null / no benefit RCT supported

An honest negative: in a 12-week randomized, double-blind, placebo-controlled trial in people with overweight/obese type 2 diabetes, both groups lost weight and lowered HbA1c, with no significant between-group differences overall. Benefit appeared only in a subgroup with low baseline gut A. muciniphila, indicating efficacy may depend on baseline colonization rather than being a universal effect.

Reported effect: Both groups showed decreases in body weight and glycated hemoglobin (HbA1c), without significant between-group differences

“Both groups showed decreases in body weight and glycated hemoglobin (HbA1c), without significant between-group differences ... [in low baseline] AKK-WST01 supplementation showed high colonization efficiency and significant reductions in body weight, fat mass, and HbA1c, which were not found in the placebo group ... [in high baseline] poor colonization and no significant clinical improvements”

Source: PMID 39879980 · Zhang 2025 · Cell Metab

Respiratory Symptoms

RCT supported

-0.8BCSS diff · p=0.004
-1.4 to -0.395% CI

In a separate double-blind randomized controlled trial, a heat-killed A. muciniphila strain (ETB-F01) outperformed placebo on a breathlessness/cough/sputum symptom scale over 12 weeks, with no serious adverse events. Lung-function trends did not reach significance and several secondary symptom scores were unchanged, so this is an early single-trial signal in a distinct application area.

Reported effect: ETB-F01 had a superior efficacy over placebo in improving BCSS total scores (between-group difference = -0.8 (95% confidence interval, -1.4--0.3), p-value = 0.004)

“ETB-F01 had a superior efficacy over placebo in improving BCSS total scores (between-group difference = -0.8 (95% confidence interval, -1.4--0.3), p-value = 0.004) ... While trends toward improvement in lung function were noted, statistical significance was not achieved ... ETB-F01 did not cause any serious adverse events”

Source: PMID 39683507 · Lee 2024 · Nutrients

Dosage (research context · not a recommendation)

Educational reference, not a dosing recommendation. The pivotal exploratory human study (Depommier 2019) used ~10^10 cells/day of pasteurized A. muciniphila for 3 months; EU novel-food authorization caps use at <=3.4x10^10 cells/day in adults. Confirmatory efficacy trials are limited.

Regulatory Status · 4 Markets

US · FDA: Lawful US dietary ingredient: pasteurized A. muciniphila strains have completed FDA NDI notification (HealthBiome HB05P low-dose acknowledged Dec 2024; AKK PROBIO NDI 2026) and a strain holds self-affirmed GRAS (2024) for live and pasteurized forms. Structure/function claims only; NO FDA-authorized health claim.
EU · EFSA: Pasteurized A. muciniphila is an authorized EU novel food (Commission Implementing Regulation (EU) 2022/168; EFSA 2021 positive safety opinion, A-mansia Biotech) for food supplements (Dir 2002/46/EC) and FSMP at <=3.4x10^10 cells/day in adults (excl. pregnant/lactating). NO authorized Reg 432/2012 health claim.
CN · China: Not approved as a China novel food ingredient; only an Akkermansia muciniphila fermented-lysate cosmetic notification is pending (June 2025), with no food/supplement approval — not lawfully marketable as a food/supplement ingredient in China.
BR · ANVISA: No ANVISA record of A. muciniphila on the permitted probiotic-strain or dietary-supplement (RDC 243/2018) list; as a next-generation strain it is not an established listed ingredient and has no confirmed Brazilian market-access path. No Anexo V functional claim.

Safety

Pasteurized A. muciniphila was well tolerated in the small exploratory human study and judged safe by EFSA for adults at <=3.4x10^10 cells/day. Human efficacy evidence is early (one small proof-of-concept RCT plus preclinical work) — benefits are emerging, not established (evidence grade C). Not assessed for pregnant/lactating women or children (excluded from EU authorization). Live vs pasteurized forms differ; caution in immunocompromised individuals. Educational, not medical advice.

Goals: gut-digestion · weight-management

Lifestyles: weight-management · glp-1-companion

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

PMID 31263284 · Depommier 2019 · Nat Med — Insulin Sensitivity & Metabolic Markers
PMID 39879980 · Zhang 2025 · Cell Metab — Type 2 Diabetes / Weight — Overall Null
PMID 39683507 · Lee 2024 · Nutrients — Respiratory Symptoms

Frequently Asked Questions

1. What is Akkermansia muciniphila and is it a recognized supplement ingredient?

It is a mucin-degrading gut commensal developed as a next-generation probiotic, usually supplied in a pasteurized form. Pasteurized A. muciniphila is an authorized EU novel food (Reg (EU) 2022/168) and a lawful US dietary ingredient via FDA NDI notification and self-affirmed GRAS. Only structure/function claims are permitted; there is no FDA- or EFSA-authorized health claim.

2. What dose was used and is it considered safe?

The pivotal human study used roughly 10^10 pasteurized cells/day for three months, and EU novel-food authorization caps adult use at <=3.4x10^10 cells/day, excluding pregnant/lactating women and children. Pasteurized cells were well tolerated in trials and judged safe by EFSA for adults; live versus pasteurized forms differ, and caution is advised in immunocompromised individuals. This is educational information, not dosing or medical advice.

Last evidence review: 2026-06-22

← Evidence library